secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2026-10-15T11:02:30+00:00
Accession:  0001711279-26-000064
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Krystal Biotech KB113 pilot: 83% of BCC lesions regressed in 3 Gorlin syndrome patients
--------------------------------------------------------------------------------

- Over 80% of assessed landmark lesions regressed: 69/83 (83.1%) any regression; 42/83 (50.6%) >50% reduction; 8/83 (9.6%) at least 90% reduction.
- Substantial regression in non-injected lesions (40/47, 85.1%) suggests an abscopal effect; all three biopsied injected lesions showed histologically confirmed complete response.
- Three adults received six intralesional doses of up to 2 mL of 10^8 PFU/mL KB113 over 14 weeks; all 22 adverse events were mild/moderate and resolved, with no serious AEs.
- KB113 is the low dose of intratumoral KB707 from OPAL-1 (NCT05970497); Krystal has begun FDA discussions on advanced development for Gorlin syndrome.
- Data presented by investigator Dr. Shireen Guide at the 14th PeDRA Annual Conference, Oct 15-17, 2026; US Gorlin syndrome prevalence may exceed 10,000 patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127926000064/0001711279-26-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127926000064/krys-20261015.htm
  HTML page:      https://secwatch.observer/filing/0001711279-26-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer